|
Halozyme Therapeutics, Inc. - Company Profile Snapshot
| Company Profile: |
Halozyme Therapeutics, Inc. |
| Ticker: |
HALO |
| Exchanges: |
NAS |
| 2008 Sales: |
8,764,100 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
129 |
Business Description
Halozyme Therapeutics, Inc.. The Group's principal activity is to develop and commercialize recombinant human enzymes for the ophthalmology and oncology markets. It's business is in the development stage. Its portfolio of products in development stage is based on intellectual property covering the family of human enzymes known as hyaluronidases. The Halozyme's product offerings comprise Cumulase and Enhanze SC. The Cumulase is an ex vivo formulation of recombinant human PH20 to replace the bovine and ovine enzymes used for the preparation of oocytes prior to in-vitro fertilization and cryopreservation during the process of intracytoplasmic sperm injection, in which the enzyme is an essential component. Its Enhanze SC is a low unit, fast-acting local formulation of rHuPH20 to replace Wydase. The Enhanze SC also facilitates the penetration and dispersion of other drugs by temporarily opening flow channels under the skin.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
